Company Legal Name
Latest Valuation
Founded Year
Headquarters
Tessera Therapeutics develops advanced biotechnology tools for writing precise, permanent genetic changes to treat inherited diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company positions itself at the forefront of gene editing technology, focusing on creating therapeutic solutions that go beyond traditional approaches by enabling targeted genetic modifications. Tessera's proprietary platform addresses the significant medical need for treating genetic disorders through permanent genetic corrections rather than temporary interventions. The company continues to advance its gene writing capabilities, working toward clinical applications that could transform treatment paradigms for patients with inherited genetic conditions requiring precise therapeutic interventions.
Availability of information and platform features may vary by region and applicable requirements.
Eligibility and access may depend on user location, verification status, and applicable legal or regulatory requirements.
Additional platform details may be available after account creation, where applicable.
Identity, compliance, and other review steps may be required before access to certain materials or features.
Platform details, if applicable, should be reviewed in account materials before making any decision.
Any economic terms, if applicable, should be reviewed carefully in the relevant materials.
Private market interests may be illiquid, restricted, or difficult to transfer. Users should not assume that any secondary market will be available.
Valuations may reflect past financing rounds or other available information and may not represent a price at which any person can transact.
Company and sector risks may vary by business model, technology development, competition, regulation, and market conditions.
Operational, documentation, custody, or verification processes may involve limitations, delays, or dependencies.
Regulatory, tax, and legal requirements may change and may affect information availability, platform features, or user eligibility.
